drugset
drugset / Trial / NCT01374620

Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel

NCT01374620 ↗

Phase 1 Completed 28 enrolled Centre Oscar Lambret
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of the study is to determine the MTD of Paclitaxel in association with metronomic Cyclophosphamide.

Timeline

Start
2011-07-13
Primary completion
2013-02
Completion
2013-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 50 mg Oral
Subject Paclitaxel Small molecule 40 mg Intravenous
Subject Paclitaxel Small molecule 60 mg Intravenous
Subject Paclitaxel Small molecule 70 mg Intravenous
Subject Paclitaxel Small molecule 75 mg Intravenous
Subject Paclitaxel Small molecule 80 mg Intravenous
Subject Paclitaxel Small molecule 85 mg Intravenous
Subject Paclitaxel Small molecule 90 mg Intravenous

Indications

cancer